Ultragenyx Pharmaceutical (RARE) Return on Equity (2014 - 2026)

Ultragenyx Pharmaceutical (RARE) has 13 years of Return on Equity data on file, last reported at 0.04% in Q1 2026.

• Quarterly Return on Equity rose 4.0% year-over-year to 0.04% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.04% (up 4.0% YoY) and the FY2025 annual result came in at 0.07%, down 7.0% from the prior year.
• Return on Equity slipped to 0.04% in Q1 2026 per RARE's latest filing, from 0.16% in the prior quarter.
• Across five years, Return on Equity topped out at 0.16% in Q4 2025 and bottomed at 0.08% in Q3 2023.
• The 5-year median for Return on Equity is 0.01% (2022), against an average of 0.01%.
• The widest annual swing landed in 2023, when Return on Equity dropped 7 bps; it then gained 16 bps in 2025.
• Tracing RARE's Return on Equity over 5 years: stood at 0.02% in 2022, then tumbled by 129 bps to 0.04% in 2023, then surged by 99 bps to 0.0% in 2024, then surged by 69874 bps to 0.16% in 2025, then sank by 76 bps to 0.04% in 2026.
• Per Business Quant, the three latest RARE Return on Equity figures stand at 0.04% (Q1 2026), 0.16% (Q4 2025), and 0.0% (Q3 2025).

Peer Comparison